Molecular docking simulation was used to verify that the predicted targets FN1 and MMP9 can bind to current therapeutic drugs such as Acetylsalicylic acid, suggesting the possibility of FN1 and MMP9 as new targets for AIS treatment. Here, MMP9 is linked to androgen insensitivity syndrome.